# Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

> **NCT07341867** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Andrew Hantel, MD** · enrollment: 90 (estimated)

## Conditions studied

- Multiple Myeloma
- Triple Negative Breast Cancer
- Duffy Blood Group, Chemokine Receptor Gene Mutation
- Duffy Blood Group, Chemokine Receptor Gene C.-67T>C

## Interventions

- **DRUG:** Dexamethasone
- **DRUG:** Bortezomib
- **DRUG:** LENALIDOMIDE
- **DRUG:** Daratumumab
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Pembrolizumab
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin

## Key facts

- **NCT ID:** NCT07341867
- **Lead sponsor:** Andrew Hantel, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2028-03-31
- **Final completion:** 2029-03-31
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07341867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07341867, "Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07341867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*